drugset

drugset / Trial / NCT00913653

Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure

NCT00913653 ↗

Phase 2 Completed 30 enrolled Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study assess the safety/tolerability, PK/PD of LCZ696 in patients with stable heart failure.

Timeline

Start: 2009-05
Primary completion: 2009-07
Completion: —

Publications

Results Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D, Chandra P, Ayalasomayajula S, Prescott MF, Pal P, Langenickel TH, Jordaan P, Rajman I. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. Cardiovasc Ther. 2016 Aug;34(4):191-8. doi: 10.1111/1755-5922.12183.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LCZ696	Unknown	200 mg	—

Indications